Amylyx Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Amylyx Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 88% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-181.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 88% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / -15%In 3 years sales changed by -100% while total assets changed by -15%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-98.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 83% of Healthcare companies in United States.
Cash Cushion Ratio
+9%Cash, after subtracting all debt, equals 9% of its market value (net cash).
Lower than 51% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Amylyx Pharmaceuticals, Inc. made a loss over the last year. Amylyx Pharmaceuticals, Inc. owes $0.10 for every $1 it owns. Amylyx Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAmylyx Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
14.99The share price is 14.99 times Amylyx Pharmaceuticals, Inc.'s book value per share, higher than 90% of Healthcare companies in United States.
Market cap
$3.6 BThe total market value of all of Amylyx Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 81% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$239 MWhat Amylyx Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.91Net worth divided by the number of shares. The share price of $28.57 is 15.0 times this, which is the P/B above.
Return on equity (ROE)
-74.7%Amylyx Pharmaceuticals, Inc. lost 74.7% of its shareholders' money over the last year, lower than 63% of Healthcare companies in United States.
Owes vs Owns
0.10×Amylyx Pharmaceuticals, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Dividend yield
NoneAmylyx Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossAmylyx Pharmaceuticals, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashAmylyx Pharmaceuticals, Inc. held $311 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Amylyx Pharmaceuticals, Inc.: $3.6 B ÷ $239 M (30 Jun 2026) = 15.0.
What is Amylyx Pharmaceuticals, Inc.'s return on equity?
Amylyx Pharmaceuticals, Inc. lost 74.7% of its shareholders' money over the last year, lower than 63% of Healthcare companies in United States.
How much does Amylyx Pharmaceuticals, Inc. owe compared with what it owns?
Amylyx Pharmaceuticals, Inc. owes $0.10 for every $1 it owns (low), lower than 87% of Healthcare companies in United States.
Does Amylyx Pharmaceuticals, Inc. pay a dividend?
No. Amylyx Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.